ReviewInternational journal of molecular sciences2020
Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Risk factors for venous thromboembolism in sickle cell disease.Research and practice in thrombosis and haemostasis · 2026Article
- Correlation Between Von Willebrand Factor, Thrombin-Antithrombin Complex, and Disease Severity in Sickle Cell Disease: Implications for Thrombosis.Journal of blood medicine · 2026Article
- Sickle cell disease: managing thromboembolism.Hematology. American Society of Hematology. Education Program · 2025Review
- Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.BMC infectious diseases · 2025Article
- Abnormalities of hemostasis in sickle cell patients and predisposition to thrombotic risk: a systematic review and meta-analysis.Thrombosis journal · 2025Review
- Clotting, inflammation, and immunity: the multifaceted role of platelets in HIV and sickle cell disease - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Polymorphic Distribution of Human Homeostatic Iron Regulator Gene H63D rs1799945 and Clinico-Hematological Parameters of Sickle Cell Anemia Patients: A Case-Control Study in Northern Ghana.Health science reports · 2025Article
- Article
- Article
- Biased agonism of protease-activated receptor-1 regulates thromboinflammation in murine sickle cell disease.Blood advances · 2024Article
- Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.Research and practice in thrombosis and haemostasis · 2024Article
- Review
- A Miraculous Save: Gangrenous Bowel and Meckle's Diverticulum With Acute Superior Mesenteric Artery Thrombosis.Cureus · 2024Article
- Venous thromboembolism in orthopedic surgery: Global guidelines.Acta orthopaedica et traumatologica turcica · 2023Review
- Molecular and environmental contributors to neurological complications in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Review
- Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.Blood · 2023Article
- COVID-19 and Sickle Cell Disease: Two Independent Risk Factors for Venous Thromboembolism.Cureus · 2023Review
- Targeting the von Willebrand Factor-ADAMTS-13 axis in sickle cell disease.Journal of thrombosis and haemostasis : JTH · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is an important cause of vascular morbidity and mortality. Many risk factors have been identified for venous thrombosis that lead to alterations in blood flow, activate the vascular endothelium, and increase the propensity for blood coagulation. However, the precise molecular and cellular mechanisms that cause blood clots in the venous vasculature have not been fully elucidated. Patients with sickle cell disease (SCD) demonstrate all the risk factors for venous stasis, activated endothelium, and blood hypercoagulability, making them particularly vulnerable to VTE. In this review, we will discuss how mouse models have elucidated the complex vascular pathobiology of SCD. We review the dysregulated pathways of inflammation and coagulation in SCD and how the resultant hypercoagulable state can potentiate thrombosis through down-regulation of vascular anticoagulants. Studies of VTE pathogenesis using SCD mouse models may provide insight into the intersection between the cellular and molecular processes involving inflammation and coagulation and help to identify novel mechanistic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.